0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Contribution |

Cognitive Decline in Prodromal Alzheimer Disease and Mild Cognitive Impairment FREE

Robert S. Wilson, PhD; Sue E. Leurgans, PhD; Patricia A. Boyle, PhD; David A. Bennett, MD
[+] Author Affiliations

Author Affiliations: Rush Alzheimer's Disease Center and the Departments of Neurological (Drs Wilson, Leurgans, and Bennett) and Behavioral Sciences (Drs Wilson and Boyle), Rush University Medical Center, Chicago, Illinois.


Arch Neurol. 2011;68(3):351-356. doi:10.1001/archneurol.2011.31.
Text Size: A A A
Published online

Objective  To characterize the course of cognitive decline during the prodromal phase of Alzheimer disease.

Design  Longitudinal cohort study with up to 16 years of observation.

Participants  Older persons from 2 studies underwent annual clinical evaluations that included cognitive function testing and clinical classification of mild cognitive impairment, dementia, and Alzheimer disease. At baseline, there were 2071 individuals without dementia and 1511 without cognitive impairment.

Results  During follow-up, 462 persons developed Alzheimer disease (20 with dementia solely due to another condition were excluded). Five to six years before diagnosis, the rate of global cognitive decline accelerated more than 15-fold. The acceleration in cognitive decline occurred slightly earlier for semantic memory (76 months before diagnosis) and working memory (75 months) than other cognitive functions. Mild cognitive impairment was also preceded by years of cognitive decline that began earlier (80 months before diagnosis) and proceeded more rapidly (annual loss of 0.102 unit) in the amnestic than in the nonamnestic (62 months, 0.072 unit) subtype.

Conclusion  Dementia due to Alzheimer disease is preceded by about 5 to 6 years of accelerated decline in multiple cognitive functions. By contrast, little decline is evident in persons who do not develop Alzheimer disease.

Figures in this Article

Dementia due to Alzheimer disease (AD), by definition, is preceded by a minimum of 6 months of cognitive decline. With recognition of the importance of developing strategies to delay the onset of AD symptoms,1,2 scientific interest in the prodromal cognitive changes has increased. There have been relatively few prospective longitudinal studies of this prodromal phase of the disease,39 however, and estimates of its duration range from about 1 year6 to more than 10.5 Several factors probably contribute to this variability. One is that most studies have had fewer than 100 subjects with incident disease.3,79 In addition, prodromal changes may occur earlier in some cognitive domains than others.6,8 Studies also likely differ in the cutoff point between cognitive normality and dementia.

Here we examine change in cognitive function during the prodromal phase of AD and before the onset of mild cognitive impairment (MCI), a common precursor to dementia in AD. The data are from 2 longitudinal cohort studies, the Religious Orders Study10 and the Rush Memory and Aging Project.11 For up to 16 years, more than 2000 participants underwent annual clinical evaluations that included detailed testing of cognitive function and clinical classification of MCI, dementia, and AD. In mixed-effects models that allowed rate of cognitive change to shift, we characterized the change in global and specific measures of cognition in the years preceding and following dementia onset in AD and conducted similar analyses of cognitive change before and after incidence of MCI.

PARTICIPANTS

The subjects are from 2 ongoing longitudinal studies, the Religious Orders Study, which began in 1994, and the Rush Memory and Aging Project, which began in 1997. Both studies involve annual clinical evaluation and brain donation at death and were approved by the institutional review board of Rush University Medical Center.

At the time of the analyses, 2323 individuals had completed the baseline evaluations and been found to be without dementia. Of these, 62 died before follow-up and 40 had been in the study less than 1 year. This left 2221 individuals eligible for follow-up; 2071 (93.2%) had follow-up data. The first set of analyses are based on this group. They completed a mean (SD) of 7.4 (3.8) annual evaluations. At baseline, they had a mean (SD) age of 77.4 (7.7) years, a mean (SD) of 16.2 (3.8) years of education, and a mean (SD) score of 28.2 (1.9) on the Mini-Mental State Examination; 72.0% were women; and 87.9% were white and not Hispanic. A second set of analyses focused on a subset of this group: 1511 persons without MCI or dementia at baseline. They completed a mean (SD) of 7.8 (3.9) annual evaluations and had a mean (SD) baseline age of 76.3 (7.4) years and mean (SD) of 16.4 (3.8) years of education; 72.8% were women; and 90.7% were white and not Hispanic.

CLINICAL EVALUATION

At baseline and annually thereafter, subjects in each study underwent a uniform structured clinical evaluation that included a medical history, complete neurological examination, and cognitive performance testing. Based on these data and in-person evaluation of the subjects, an experienced clinician diagnosed dementia and AD using the criteria of the joint working group of the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association.12 The criteria require a history of cognitive decline and impairment in at least 2 cognitive domains, one of which must be memory for a diagnosis of AD. As previously described,13 impairment in 5 cognitive functions (orientation, attention, memory, language, and visuospatial ability) was determined in a 2-step process. First, an algorithm rated impairment in each area of function based on educationally adjusted cutoff scores on 11 individual tests.14 Second, based on all test data and information on education, sensorimotor problems, and effort, a neuropsychologist agreed or disagreed with each rating and supplied a new rating in the event of disagreement. Persons who had cognitive impairment but did not meet criteria for dementia were classified as having MCI and divided into amnestic (ie, with episodic memory impaired) and nonamnestic subtypes, as previously described.15 Individuals who met these criteria for MCI have been found to have intermediate levels of mortality,14,16 cognitive decline,14,17,18 and plaques, tangles, and cerebral infarction19 relative to persons without cognitive impairment and dementia. All clinical classification was done blinded to previously collected data.

ASSESSMENT OF COGNITIVE FUNCTION

Nineteen cognitive performance tests were administered in each study. The Mini-Mental State Examination was used for descriptive purposes and Complex Ideational Material was used only in clinical classification. Analyses were based on the remaining 17 tests. There were 7 measures of episodic memory: Word List Memory, Recall, and Recognition plus immediate and delayed recall of the East Boston story and story A from Logical Memory; 3 measures of semantic memory: verbal fluency, a 15-item form of the Boston Naming Test, and a measure of reading recognition; 3 measures of working memory: Digit Span Forward, Digit Span Backward, and Digit Ordering; 2 measures of perceptual speed: Number Comparison and Symbol Digit Modalities Test; and 2 measures of visuospatial ability: short forms of Judgment of Line Orientation and Standard Progressive Matrices. The primary outcome was a composite measure of global cognition using all 17 individual measures. Raw scores on each of the 17 measures were converted to z scores using the baseline mean and standard deviation of all subjects; z scores were then averaged to yield the composite measure of global cognition. Based in part on previous factor analyses of these cognitive measures in these2022 and other23,24 cohorts, individual cognitive measures were grouped into specific cognitive domains. Within each domain, individual z scores were averaged to yield composite scores that were used in secondary analyses: episodic memory (based on 7 individual measures), semantic memory (3 measures), working memory (3 measures), perceptual speed (2 measures), and visuospatial ability (2 measures). Further information on the individual tests and the derivation of the composite scores is described previously.2022

STATISTICAL ANALYSIS

We used mixed-effects regression models25 to characterize paths of change in cognitive function. The models include change points that allowed rate of cognitive change to shift at some time before AD (or MCI) was diagnosed and again at the time of diagnosis. To identify the point before diagnosis when rate of cognitive change shifted, we constructed a series of models with change points ranging from a few months to several years before diagnosis and chose the analysis with the highest log-likelihood value, indicating the best model fit. To take advantage of all cognitive data, a composite measure of global cognition was the primary outcome. For AD, we conducted additional analyses excluding those with MCI at baseline and using composite measures of specific cognitive domains as outcomes. For MCI, the core model was followed by separate analyses of MCI subtypes. All analyses controlled for age, sex, and education. Programming was done in SAS (SAS Inc, Cary, North Carolina).26

COGNITIVE DECLINE IN THE PRODROMAL PHASE OF AD

The 2071 persons without dementia at study enrollment had up to 16 years of annual follow-up (mean [SD], 7.0 [4.0]). During this period, 462 persons developed incident AD. For these analyses, we excluded the 20 people who developed other forms of dementia. Those who developed AD were older than those who did not (81.3 vs 76.3 year; t845 = 14.1; P < .001) but the groups were similar in education (16.4 vs 16.2 years; t2049 = 1.4; P = .16) and sex distribution (72.7% women vs 71.9% men; χ21 = 0.1; P = .74).

We used mixed-effects models to characterize the change in cognitive function before and after AD was clinically diagnosed. To determine if the rate of decline accelerated at some point before the diagnosis, we fit a series of models that allowed for a shift in rate of cognitive change during periods ranging from 6 to 120 months before the diagnosis plus a second shift at the time of diagnosis. We used a composite measure of global cognition in initial analyses. At baseline, scores ranged from −1.910 to 1.466 (mean [SD], 0.094 [0.529]), with higher values indicating better function. The best-fitting model set the point of change at 65 months before diagnosis. In this model (Table 1), the global cognitive score declined a mean of 0.013 units per year before the point of change and 0.209 units per year thereafter, a more than 15-fold increase. After AD was diagnosed, there was a further increase of about one-third in annual rate of global cognitive decline. Figure 1, which is based on this analysis, shows the predicted 10-year paths of change in global cognition for 2 typical participants. Little cognitive decline is evident in the person who remained dementia free. In the person who developed AD, the diagnosis in study year 7 was preceded by more than 5 years of accelerated global cognitive decline.

Place holder to copy figure label and caption
Figure 1.

Global cognitive decline before and after dementia onset in Alzheimer disease (AD). Predicted 10-year paths of decline in global cognition for typical participants who remained dementia free or developed AD in study year 7, adjusted for age, sex, and education.

Graphic Jump Location
Table Graphic Jump LocationTable 1. Change in Cognitive Function Before and After Dementia Onset in Alzheimer Diseasea

At baseline, 552 subjects had MCI. To assess how this subgroup affected results, we excluded them and repeated the analyses in the remaining 1499, of whom 217 developed AD. The best-fitting change point was at 54 months before AD was diagnosed. Global cognition declined a mean of 0.016 units per year before this point (standard error [SE], 0.001; P < .001). The rate of annual decline increased more than 15-fold to 0.262 units (SE, 0.008; P < .001) during the 54-month prodromal period and to 0.314 units (SE, 0.021; P = <.001) after AD was diagnosed.

To see if results varied across cognitive domains, we conducted separate analyses using composite measures of specific cognitive functions (Table 1). As shown in Figure 2, the prodromal period began about 63 months before dementia onset for episodic memory, 76 months for semantic memory, 75 months for working memory, 70 months for perceptual speed, and 65 months for visuospatial ability. Prior to the prodromal period, episodic memory was stable and there was gradual decline in the other domains. Decline in all functions increased sharply during the prodromal period with less marked acceleration after AD was diagnosed.

Place holder to copy figure label and caption
Figure 2.

Decline in specific cognitive functions before and after dementia onset in Alzheimer disease. Predicted 10-year paths of cognitive decline for typical participants who remained dementia free or developed AD in study year 7, adjusted for age, sex, and education.

Graphic Jump Location
COGNITIVE DECLINE IN THE PRODROMAL PHASE OF MCI

To further examine prodromal AD, we assessed the change in cognitive function during the development of MCI, widely recognized as a precursor to AD. Of 1511 persons without cognitive impairment at study enrollment, 742 developed cognitive impairment on follow-up. Those who developed MCI were older (78.1 vs 74.6 years; t1509 = 9.4; P < .001) and slightly more educated (16.6 vs 16.2 years; t1509 = 1.9; P = .05) than those who did not, with a comparable sex distribution (71.0% women vs 74.5% men; χ21 = 2.3; P = .13). There was an approximately 4.5-year period of gradual global cognitive decline prior to MCI onset (as shown by the term for time during prodrome in Table 2), with a further doubling in the rate of decline after MCI was diagnosed.

Table Graphic Jump LocationTable 2. Change in Global Cognitive Function Before and After Onset of Mild Cognitive Impairmenta

Because memory impairment in MCI has been associated with increased risk of dementia and AD,27,28 we conducted separate analyses for amnestic (observed in 487 patients) and nonamnestic (observed in 442 patients) MCI to examine their developmental histories (Table 2; Figure 2). A mean of 80 months before the diagnosis of amnestic MCI (Figure 3A), the annual rate of global cognitive decline increased more than 10-fold, with a further increase of about 80% following diagnosis. By contrast, in nonamnestic MCI (Figure 3B) the prodromal period began later (62 months before diagnosis) and the acceleration in global cognitive decline was less marked, with an approximately 2.5-fold increase during the prodromal period and a further 50% increase following diagnosis.

Place holder to copy figure label and caption
Figure 3.

Global cognitive decline before and after onset of amnestic (A) or nonamnestic (B) mild cognitive impairment (MCI).

Graphic Jump Location

In a group of more than 2000 elderly people followed up annually for up to 16 years, we assessed the change in cognitive function during the prodromal phases of AD and its precursor, MCI. The rate of cognitive decline increased sharply about 5 to 6 years before dementia was diagnosed and showed a modest increase approximately 4 to 6 years before MCI was diagnosed. The results indicate that dementia in AD is preceded by many years of progressively accelerating cognitive decline.

We are aware of only one previous study of cognitive change preceding development of MCI, and the results were comparable with ours, with accelerated cognitive decline occurring 3 to 4 years before MCI diagnosis.9 In addition, we found that the prodromal period for amnestic MCI began 1 to 2 years earlier than the nonamnestic MCI prodrome and was characterized by more rapid cognitive decline. These findings are consistent with neuroimaging29 and neuropathologic19 data suggesting that many people with amnestic MCI actually have mild AD.

As noted above, estimates of the temporal course of cognitive decline prior to dementia onset in AD have varied widely. The 5 to 6 years of cognitive decline preceding dementia observed in our study is close to the midpoint of comparable studies.38 Several factors probably contribute to this variability. One suggested by our analyses is the extent to which symptomatic individuals are included. When we excluded people with MCI at baseline, the prodromal period was briefer, and the acceleration of cognitive decline was more marked. This may be because individuals with milder disease take longer to transition from no cognitive impairment to dementia and are thus less likely to be identified with observation periods of fewer than 2 or 3 decades. Another factor contributing to variability in findings is study differences in the effective cutoff point for dementia. Thus, in a diagnostic system that regards MCI as mild AD,30 the cognitive prodromal period is relatively brief.6 By contrast, in the study with the longest estimate of the prodromal period,5 the mean Mini-Mental State Examination score in the pre-AD group declined to below 20 before the diagnosis was made, a relatively low dementia cutoff point.

There is also evidence that prodromal cognitive decline in AD varies across cognitive domains. We found that prodromal decline in semantic memory and working memory preceded decline in other cognitive domains, consistent with findings from a previous epidemiologic study.5 However, the differences between domains in this study were not large, and other studies suggest that prodromal decline in AD begins in other domains, including episodic memory8 and visuospatial ability.6 Thus, cognition is clearly globally affected in the prodromal phase of AD, and some of the variability between cognitive outcomes probably reflects metric factors, including retest effects,31 rather than the cognitive domain being assessed. On the other hand, prodromal cognitive decline in amnestic MCI began earlier and progressed more rapidly than in nonamnestic MCI, consistent with neuropathologic32,33 and neuroimaging34,35 data suggesting that medial temporal lobe structures that support episodic memory are among the first brain regions affected by the disease.

These data show that by the time individuals meet clinical criteria for a diagnosis of AD, they have already experienced many years of accelerating cognitive decline. This has important public health implications because it is generally assumed that treatments for AD will be more effective if introduced before this prodromal period begins and cognitive systems are manifestly dysfunctional. Further, an effective early treatment could compress the cognitive morbidity of AD,36 whereas effective treatment after dementia onset might prolong it, underscoring the need for biologic and behavioral markers to aid in early diagnosis.

Little cognitive decline was evident in people who did not develop MCI or AD. This observation is consistent with prior research5,6,37,38 and suggests that cognitive decline may not be an inevitable consequence of old age.

Strengths and limitations of this study should be noted. Clinical classification of MCI, dementia, and AD was based on a uniform clinical evaluation and widely accepted criteria applied by experienced clinicians, thereby minimizing diagnostic error. The large cohort, high rate of follow-up participation, and availability of previously established psychometrically sound measures of cognition allowed us to capture subtle nonlinear changes in function. The principal limitation is that subjects are selected, and so the generalizability of the findings will need to be established.

Correspondence: Robert S. Wilson, PhD, Rush Alzheimer's Disease Center, Rush University Medical Center, 600 S Paulina Ave, Ste 1038, Chicago, IL 60612 (rwilson@rush.edu).

Accepted for Publication: July 6, 2010.

Author Contributions:Study concept and design: Wilson and Bennett. Acquisition of data: Wilson and Bennett. Analysis and interpretation of data: Wilson, Leurgans, Boyle, and Bennett. Drafting of the manuscript: Wilson. Critical revision of the manuscript for important intellectual content: Wilson, Leurgans, Boyle, and Bennett. Statistical analysis: Leurgans. Obtained funding: Wilson and Bennett. Administrative, technical, and material support: Wilson, Boyle, and Bennett. Study supervision: Bennett.

Financial Disclosure: None reported.

Funding/Support: This study was supported by National Institute on Aging grants R01 AG17917, R01 AG024871, R01 AG15819, and P30 AG10161, and the Illinois Department of Public Health.

Role of the Sponsor: The sponsors had no role in the design or conduct of the study; in the collection management, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript.

Additional Contributions: The authors thank the many Illinois residents who have participated in the Rush Memory and Aging Project and the many Catholic nuns, priests, and brothers who have participated in the Religious Orders Study; Traci Colvin, MPH, Julie Bach, MSW, George Hoganson, and Tracy Faulkner for coordinating the studies; Woojeong Bang, MS, for statistical programming; John Gibbons, MS, and Greg Klein for data management; and Priya Patel for preparing the manuscript.

Brookmeyer  RGray  SKawas  C Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88 (9) 1337- 1342
PubMed
Sloane  PDZimmerman  SSuchindran  C  et al.  The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002;23213- 231
PubMed
Hall  CBLipton  RBSliwinski  MStewart  WF A change point model for estimating the onset of cognitive decline in preclinical Alzheimer's disease. Stat Med 2000;19 (11-12) 1555- 1566
PubMed
Amieva  HJacqmin-Gadda  HOrgogozo  JM  et al.  The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005;128 (pt 5) 1093- 1101
PubMed
Amieva  HLe Goff  MMillet  X  et al.  Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008;64 (5) 492- 498
PubMed
Johnson  DKStorandt  MMorris  JCGalvin  JE Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009;66 (10) 1254- 1259
PubMed
Small  BJBäckman  L Longitudinal trajectories of cognitive change in preclinical Alzheimer's disease: a growth mixture modeling analysis. Cortex 2007;43 (7) 826- 834
PubMed
Grober  EHall  CBLipton  RBZonderman  ABResnick  SMKawas  C Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 2008;14 (2) 266- 278
PubMed
Howieson  DBCarlson  NEMoore  MM  et al.  Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc 2008;14 (2) 192- 198
PubMed
Wilson  RSBienias  JLEvans  DABennett  DA Religious Orders Study: overview and change in cognitive and motor speed. Aging Neuropsychol Cogn 2004;11280- 30310.1080/13825580490511125
Bennett  DASchneider  JABuchman  ASMendes de Leon  CBienias  JLWilson  RS The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology 2005;25 (4) 163- 175
PubMed
McKhann  GDrachman  DFolstein  MKatzman  RPrice  DStadlan  EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34 (7) 939- 944
PubMed
Bennett  DASchneider  JAAggarwal  NT  et al.  Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology 2006;27 (3) 169- 176
PubMed
Bennett  DAWilson  RSSchneider  JA  et al.  Natural history of mild cognitive impairment in older persons. Neurology 2002;59 (2) 198- 205
PubMed
Wilson  RSSchneider  JAArnold  SETang  YBoyle  PABennett  DA Olfactory identification and incidence of mild cognitive impairment in older age. Arch Gen Psychiatry 2007;64 (7) 802- 808
PubMed
Wilson  RSAggarwal  NTBarnes  LLBienias  JLMendes de Leon  CFEvans  DA Biracial population study of mortality in mild cognitive impairment and AD. Arch Neurol 2009;66767- 772
Boyle  PAWilson  RSAggarwal  NTTang  YBennett  DA Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006;67 (3) 441- 445
PubMed
Wilson  RSAggarwal  NTBarnes  LLMendes de Leon  CFHebert  LEEvans  DA Cognitive decline in incident Alzheimer disease in a community population. Neurology 2010;74 (12) 951- 955
PubMed
Bennett  DASchneider  JABienias  JLEvans  DAWilson  RS Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005;64 (5) 834- 841
PubMed
Wilson  RSBeckett  LABarnes  LL  et al.  Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002;17 (2) 179- 193
PubMed
Wilson  RSBarnes  LLBennett  DA Assessment of lifetime participation in cognitively stimulating activities. J Clin Exp Neuropsychol 2003;25 (5) 634- 642
PubMed
Wilson  RSBarnes  LLKrueger  KRHoganson  GBienias  JLBennett  DA Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc 2005;11 (4) 400- 407
PubMed
Krueger  KRWilson  RSBennett  DAAggarwal  NT A battery of tests for assessing cognitive function in older Latino persons. Alzheimer Dis Assoc Disord 2009;23 (4) 384- 388
PubMed
Aggarwal  NTWilson  RSBienias  JL  et al.  The association of magnetic resonance imaging measures with cognitive function in a biracial population sample. Arch Neurol 2010;67 (4) 475- 482
PubMed
Laird  NMWare  JH Random-effects models for longitudinal data. Biometrics 1982;38 (4) 963- 974
PubMed
SAS Institute Inc, SAS.STAT User's Guide, Version 8.  Cary, NC SAS Institute Inc2000;
Aggarwal  NTWilson  RSBeck  TLBienias  JLBennett  DA Mild cognitive impairment in different functional domains and incident Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005;76 (11) 1479- 1484
PubMed
Yaffe  KPetersen  RCLindquist  KKramer  JMiller  B Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 2006;22 (4) 312- 319
PubMed
He  JFarias  SMartinez  OReed  BMungas  DDecarli  C Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes. Arch Neurol 2009;66 (11) 1393- 1399
PubMed
Morris  JC Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Arch Neurol 2006;63 (1) 15- 16
PubMed
Wilson  RSLi  YBienias  JLBennett  DA Cognitive decline in old age: separating retest effects from the effects of growing older. Psychol Aging 2006;21 (4) 774- 789
PubMed
Hyman  BTVan Hoesen  GWDamasio  ARBarnes  CL Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225 (4667) 1168- 1170
PubMed
Braak  HBraak  E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82 (4) 239- 259
PubMed
Killiany  RJHyman  BTGomez-Isla  T  et al.  MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 2002;58 (8) 1188- 1196
PubMed
Kesslak  JPNalcioglu  OCotman  CW Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology 1991;41 (1) 51- 54
PubMed
Wilson  RSBarnes  LLAggarwal  NT  et al.  Cognitive activity and the cognitive morbidity of Alzheimer's disease. Neurology 2010;75990- 996
Rubin  EHStorandt  MMiller  JP  et al.  A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol 1998;55 (3) 395- 401
PubMed
Wilson  RSBeckett  LABennett  DAAlbert  MSEvans  DA Change in cognitive function in older persons from a community population: relation to age and Alzheimer disease. Arch Neurol 1999;56 (10) 1274- 1279
PubMed

Figures

Place holder to copy figure label and caption
Figure 1.

Global cognitive decline before and after dementia onset in Alzheimer disease (AD). Predicted 10-year paths of decline in global cognition for typical participants who remained dementia free or developed AD in study year 7, adjusted for age, sex, and education.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Decline in specific cognitive functions before and after dementia onset in Alzheimer disease. Predicted 10-year paths of cognitive decline for typical participants who remained dementia free or developed AD in study year 7, adjusted for age, sex, and education.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Global cognitive decline before and after onset of amnestic (A) or nonamnestic (B) mild cognitive impairment (MCI).

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1. Change in Cognitive Function Before and After Dementia Onset in Alzheimer Diseasea
Table Graphic Jump LocationTable 2. Change in Global Cognitive Function Before and After Onset of Mild Cognitive Impairmenta

References

Brookmeyer  RGray  SKawas  C Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88 (9) 1337- 1342
PubMed
Sloane  PDZimmerman  SSuchindran  C  et al.  The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002;23213- 231
PubMed
Hall  CBLipton  RBSliwinski  MStewart  WF A change point model for estimating the onset of cognitive decline in preclinical Alzheimer's disease. Stat Med 2000;19 (11-12) 1555- 1566
PubMed
Amieva  HJacqmin-Gadda  HOrgogozo  JM  et al.  The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005;128 (pt 5) 1093- 1101
PubMed
Amieva  HLe Goff  MMillet  X  et al.  Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008;64 (5) 492- 498
PubMed
Johnson  DKStorandt  MMorris  JCGalvin  JE Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009;66 (10) 1254- 1259
PubMed
Small  BJBäckman  L Longitudinal trajectories of cognitive change in preclinical Alzheimer's disease: a growth mixture modeling analysis. Cortex 2007;43 (7) 826- 834
PubMed
Grober  EHall  CBLipton  RBZonderman  ABResnick  SMKawas  C Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 2008;14 (2) 266- 278
PubMed
Howieson  DBCarlson  NEMoore  MM  et al.  Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc 2008;14 (2) 192- 198
PubMed
Wilson  RSBienias  JLEvans  DABennett  DA Religious Orders Study: overview and change in cognitive and motor speed. Aging Neuropsychol Cogn 2004;11280- 30310.1080/13825580490511125
Bennett  DASchneider  JABuchman  ASMendes de Leon  CBienias  JLWilson  RS The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology 2005;25 (4) 163- 175
PubMed
McKhann  GDrachman  DFolstein  MKatzman  RPrice  DStadlan  EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34 (7) 939- 944
PubMed
Bennett  DASchneider  JAAggarwal  NT  et al.  Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology 2006;27 (3) 169- 176
PubMed
Bennett  DAWilson  RSSchneider  JA  et al.  Natural history of mild cognitive impairment in older persons. Neurology 2002;59 (2) 198- 205
PubMed
Wilson  RSSchneider  JAArnold  SETang  YBoyle  PABennett  DA Olfactory identification and incidence of mild cognitive impairment in older age. Arch Gen Psychiatry 2007;64 (7) 802- 808
PubMed
Wilson  RSAggarwal  NTBarnes  LLBienias  JLMendes de Leon  CFEvans  DA Biracial population study of mortality in mild cognitive impairment and AD. Arch Neurol 2009;66767- 772
Boyle  PAWilson  RSAggarwal  NTTang  YBennett  DA Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006;67 (3) 441- 445
PubMed
Wilson  RSAggarwal  NTBarnes  LLMendes de Leon  CFHebert  LEEvans  DA Cognitive decline in incident Alzheimer disease in a community population. Neurology 2010;74 (12) 951- 955
PubMed
Bennett  DASchneider  JABienias  JLEvans  DAWilson  RS Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005;64 (5) 834- 841
PubMed
Wilson  RSBeckett  LABarnes  LL  et al.  Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002;17 (2) 179- 193
PubMed
Wilson  RSBarnes  LLBennett  DA Assessment of lifetime participation in cognitively stimulating activities. J Clin Exp Neuropsychol 2003;25 (5) 634- 642
PubMed
Wilson  RSBarnes  LLKrueger  KRHoganson  GBienias  JLBennett  DA Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc 2005;11 (4) 400- 407
PubMed
Krueger  KRWilson  RSBennett  DAAggarwal  NT A battery of tests for assessing cognitive function in older Latino persons. Alzheimer Dis Assoc Disord 2009;23 (4) 384- 388
PubMed
Aggarwal  NTWilson  RSBienias  JL  et al.  The association of magnetic resonance imaging measures with cognitive function in a biracial population sample. Arch Neurol 2010;67 (4) 475- 482
PubMed
Laird  NMWare  JH Random-effects models for longitudinal data. Biometrics 1982;38 (4) 963- 974
PubMed
SAS Institute Inc, SAS.STAT User's Guide, Version 8.  Cary, NC SAS Institute Inc2000;
Aggarwal  NTWilson  RSBeck  TLBienias  JLBennett  DA Mild cognitive impairment in different functional domains and incident Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005;76 (11) 1479- 1484
PubMed
Yaffe  KPetersen  RCLindquist  KKramer  JMiller  B Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 2006;22 (4) 312- 319
PubMed
He  JFarias  SMartinez  OReed  BMungas  DDecarli  C Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes. Arch Neurol 2009;66 (11) 1393- 1399
PubMed
Morris  JC Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Arch Neurol 2006;63 (1) 15- 16
PubMed
Wilson  RSLi  YBienias  JLBennett  DA Cognitive decline in old age: separating retest effects from the effects of growing older. Psychol Aging 2006;21 (4) 774- 789
PubMed
Hyman  BTVan Hoesen  GWDamasio  ARBarnes  CL Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225 (4667) 1168- 1170
PubMed
Braak  HBraak  E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82 (4) 239- 259
PubMed
Killiany  RJHyman  BTGomez-Isla  T  et al.  MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 2002;58 (8) 1188- 1196
PubMed
Kesslak  JPNalcioglu  OCotman  CW Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology 1991;41 (1) 51- 54
PubMed
Wilson  RSBarnes  LLAggarwal  NT  et al.  Cognitive activity and the cognitive morbidity of Alzheimer's disease. Neurology 2010;75990- 996
Rubin  EHStorandt  MMiller  JP  et al.  A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol 1998;55 (3) 395- 401
PubMed
Wilson  RSBeckett  LABennett  DAAlbert  MSEvans  DA Change in cognitive function in older persons from a community population: relation to age and Alzheimer disease. Arch Neurol 1999;56 (10) 1274- 1279
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 44

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario